Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
about
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.Androgen receptor variation affects prostate cancer progression and drug resistance.Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.
P2860
Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Prognostic factors for clinica ...... n receptor-directed therapies.
@en
type
label
Prognostic factors for clinica ...... n receptor-directed therapies.
@en
prefLabel
Prognostic factors for clinica ...... n receptor-directed therapies.
@en
P2093
P2860
P356
P1433
P1476
Prognostic factors for clinica ...... n receptor-directed therapies.
@en
P2093
Channing J Paller
Emmanuel S Antonarakis
Hua-Ling Tsai
Mario A Eisenberger
Michael A Carducci
Rosa Nadal
Sammuel R Denmeade
Victoria J Sinibaldi
P2860
P304
P356
10.1002/PROS.23141
P577
2015-12-22T00:00:00Z